Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trialMatthew S. Davids, Jennifer R. Brown, Danielle M. Brander et al.|The Lancet Haematology|2019Cited by 72
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Doris K. Hansen, Peter A. Forsberg et al.|Journal of Hematology & Oncology|2024Cited by 46
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLLInhye E. Ahn, Matthew S. Davids, Danielle M. Brander et al.|Blood Advances|2024Cited by 12
Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic LeukemiaMatthew S. Davids, Jennifer R. Brown, Danielle M. Brander et al.|Blood|2021Cited by 4
5‐YEAR (Y) FOLLOW‐UP OF A PHASE 2 STUDY OF IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER CLL PATIENTS (PTS)Inhye E. Ahn, Matthew S. Davids, Danielle M. Brander et al.|Hematological Oncology|2023Cited by 1